Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × Melanoma, Cutaneous Malignant × Clear all

Phase

Phase 1/2 2 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 434 Breast Neoplasms 381 Neoplasms 289 Prostatic Neoplasms 192 Neoplasm Metastasis 153 Multiple Myeloma 143 Colorectal Neoplasms 121 Lung Neoplasms 104 Ovarian Neoplasms 99 Parkinson Disease 4, Autosomal Dominant Lewy Body 98 Melanoma 95 Lymphoma, Follicular 92 Recurrence 87 Papillomavirus Infections 81 Lymphoma, Non-Hodgkin 81 Leukemia, Lymphocytic, Chronic, B-Cell 80 Carcinoma, Hepatocellular 80 Stomach Neoplasms 76 Small Cell Lung Carcinoma 72 Leukemia, Myeloid, Acute 70 Pain 66 Pancreatic Neoplasms 65 Uterine Cervical Neoplasms 64 Carcinoma, Renal Cell 64 Keratosis, Actinic 63 Urinary Bladder Neoplasms 58 Lymphoma, Large B-Cell, Diffuse 53 Myasthenia Gravis 51 Leiomyoma 49 Carcinoma 49

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡